Cel Sci (CVM) Net Cash Flow (2010 - 2026)
Cel Sci (CVM) posted Net Cash Flow of -$4.4 million for Q1 2026, up 6.18% sequentially from -$4.7 million in Q4 2025, and down 63.09% YoY from -$11.9 million in Q1 2025.
Cel Sci (CVM) Net Cash Flow (2010 - 2026) Analysis & Trends
Cel Sci has reported Net Cash Flow for 16 years, with the latest figure at -$4.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 63.09% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33573.0 (up 99.01% YoY) and the FY2025 annual result came in at $6.2 million, up 949.1% from the prior year.
- Net Cash Flow improved to -$4.4 million in Q1 2026 per CVM's latest filing, from -$4.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $9.2 million in Q3 2025 and troughed at -$8.0 million in Q1 2023.
- A 5-year average of -$2.1 million and a median of -$2.8 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 5373.24% in 2022, then jumped 540.05% in 2024.
- Over 5 years, Net Cash Flow stood at -$4.7 million in 2022, then jumped by 80.57% to -$904295.0 in 2023, then jumped by 86.28% to -$124058.0 in 2024, then tumbled by 3669.11% to -$4.7 million in 2025, then climbed by 6.18% to -$4.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$4.4 million, -$4.7 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 225.59 Mn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | 4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.39 Mn |
| Mar 31, 2026 | -4.39 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Sep 30, 2025 | 9.16 Mn |
| Sep 30, 2025 | 9.16 Mn |
| Jun 30, 2025 | -131,449.00 |
| Jun 30, 2025 | -131,449.00 |
| Mar 31, 2025 | -2.69 Mn |
| Mar 31, 2025 | -2.69 Mn |
| Dec 31, 2024 | -124,058.00 |
| Dec 31, 2024 | -124,058.00 |
| Sep 30, 2024 | 4.35 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Jun 30, 2024 | -4.92 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Dec 31, 2023 | -904,295.00 |
| Dec 31, 2023 | -904,295.00 |